Therapeutic antibodies, also called humanized monoclonal antibodies, have become the talk of the town in drug development the last few decades. The antibody’s ability to bind to a specific molecule makes it very attractive in development of new treatments. Several successful antibody-based drugs have already been approved for treatments of multiple sclerosis, rheumatoid arthritis, psoriasis, and several different cancers including colorectal cancer and breast cancer. And the list keeps growing.
At Capra Science Antibodies, we have the knowledge and capability to assist clients in developing new therapeutic antibodies by humanizing monoclonal antibodies originally developed in another species. This is needed to overcome immunologic side effects effected by the drug. Capra Science also has extensive experience in producing reliable specific antibodies towards the therapeutic antibodies (or anti-ADC antibodies) for monitoring in pre-clinical and clinical trials. The specific anti-drug antibodies that we develop are often polyclonal antibodies.
At Capra Science Antibodies, we have the knowledge and capability to assist clients in developing new therapeutic antibodies by humanizing monoclonal antibodies originally developed in another species. This is needed to overcome immunologic side effects effected by the drug. Capra Science also has extensive experience in producing reliable specific antibodies towards the therapeutic antibodies (or anti-ADC antibodies) for monitoring in pre-clinical and clinical trials. The specific anti-drug antibodies that we develop are often polyclonal antibodies.
RSS Feed